|
|
|
| IL-17 as an Adjuvant Enhances Immune Responses of Recombinant Protein Vaccine |
| LOU Yao-xian1, ZOU Qiang2, JIN Jin2, WANG Xian-zheng2, ZHANG Yi-zhi2, WANG Bin2 |
1. College of Veterinary Medicine, China Agricultural University, Beijing 100193, China;
2. State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100193, China |
|
|
|
Abstract Objective: To enhance immune responses to protein vaccine, IL-17 was investigated as a molecular adjuvant to enhance humoral immune responses, especially cellular immune responses to protein vaccine. Methods: C57BL/6 mice were immunized with OVA alone, or with IL-17A by intramuscular injection. The immunization was performed on week 0, 2. The concentration of the anti-OVA IgG, the stimulated index of T lymphocyte proliferation, and the expressions of IFN-γ, IL-4 and IL-17 in CD+4 T cells and IL-17, IFN-γ in CD+8 T cells, and specific in vivo cytotoxic T lymphocyte (CTL) activity were detected on week 3,4. Results: The results showed that IL-17 as a molecular adjuvant for the protein vaccine, OVA, could enhance immune responses, especially the cellular immune responses. IL-17 could not only enhance the humoral responses and T cell proliferation, but also the expressions of IL-17 in CD+4 and CD+8 T cells, and IFN-γ in CD+8 T cells. Accordingly, the level of CTL in vivo was significantly increased. Conclusion: The results demonstrated that IL-17 as a molecular adjuvant enhanced humoral and cellular immune responses to protein vaccine, especially the CD+8 T cell-immunity. The novel functionality of IL-17 on adaptive immunity may lead to develop new protein vaccine targeted to the cellular immune responses.
|
|
Received: 31 March 2011
Published: 25 July 2011
|
|
|
|
|
|
[1] Dzierzbicka K, Kolodziejczyk A M. Adjuvants--essential components of new generation vaccines. Postepy Biochem, 2006,52(2):204-211.
[2] Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol, 2009,27(1): 485-517.
[3] Murugaiyan G, Mittal A, Weiner H L. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD+4 T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol, 2008, 181(11): 7480-7488.
[4] Wong C K, Lit L C, Tam L S, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol, 2008,127( 3): 385-393.
[5] Kehlen A, Thiele K, Riemann D, et al. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol, 2002,127(3): 539-546.
[6] 张景熙. IL-17与疾病相关的研究进展. 国外医学, 2004,27(1): 52-55. Zhang J X. Foreign Medical Sciences, 2004,27(1): 52-55.
[7] 秦霞, 刘钟滨. 白细胞介素17家族. 同济大学学报(医学版), 2003, 24(6): 519-522. Qin X, Liu Z B. Journal of Tongji University (Medical Science), 2003, 24(6): 519-522.
[8] Garley M, Jablonska E, Grabowska S Z, et al. IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma, 2009,56(2): 96-100.
[9] Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm, 2005,2005(5): 273-279.
[10] Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol, 2008,87(11): 899-904.
[11] Mitsdoerffer M, Lee Y, Kuchroo V K, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA, 2010,107(32):14292-14297.
[12] Awasthi A, Kuchroo V K. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol, 2009, 10(6): 568-570.
[13] Lindblad E B. Aluminium adjuvants-in retrospect and prospect. Vaccine,2004, 22(27-28):3658-3668.
[14] Da-Silva C A, Hartl D, Liu W, et al.TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. The Journal of Immunology, 2008,181(6): 4279-4286.
[15] Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol, 2009,10(7):778-785.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
